“we hope to see those internal programs carrying its clinical head in the next couple of years.”

In context

“able to change how one thinks about the tissue targeting component. There will be changes in terms of the linkers and for right now, there are probably two major payloads that people use microtubules based chemotherapy, as well as a TOPO1 based chemotherapy. I would just emphasize that there are only -- there are not just two classes of chemotherapy out there for the last 30 years and each one has a reason why they are there. So we have invested in an ADC platform that is separate, but we will build-off what is learn from our clinical programs both in the ones that we are doing with Daiichi Sankyo and Kelun, as well as those that we are doing when we are collaborating with others in relationship with KEYTRUDA. So we have built and we continue to build that expertise within the company and we hope to see those internal programs carrying its clinical head in the next couple of years. Rob Davis: Thanks, Geoff. Next question please. Operator: Thank you. Our next question comes from Steve Scala with TD Cowen. Your line is open. Steve Scala: Thank you very much. What is VAXNEUVANCE’s share in pediatrics now and why hasn’t it seen an inflection in the U.S. sales in line with Merck’s prior comments that it held 30% share of the pediatric market with plans to grow from there. I mean, 30% share of a $6 billion market is a big number and it’s well-ahead of where current sales are landing. So any color would be appreciated? Thank you. Rob Davis: Yeah. Steve, I will maybe jump on that and then others can jump in. But so your answer is we are in that low 30% share both in the public and private market. So that is what you are saying in the quarter. I think the U.S. roughly was ab”